Table 2.

Summary of clinical trials evaluating the safety and/or efficacy of targeted agents in advanced-stage SCLC patients

Study name	Study phase	Mechanism of action	Agent	Outcomes
ClinicalTrials.gov: NCT0228969095	I/II	PARP inhibitor	veliparib	safety: well tolerated
ClinicalTrials.gov: NCT0128698796	I	PARP inhibitor	talazoparib	safety: well tolerated
ClinicalTrials.gov: NCT0163854697	II	PARP inhibitor	veliparib	ORR: 39% versus 14% (p = 0.016)
				PFS:a 3.8 versus 2.0 (p = 0.39)
				OS:a 82 versus 7.0 (p = 0.50)
ECOG-ACRIN 251198	II	PARP inhibitor	veliparib	ORR: 71.9% versus 65.6% (p = 0.57)
				PFS: 6.1 versus 5.5 (p = 0.06)
				OS: 10.3 versus 8.9 (p = 0.17)
TAHOE99	III	DLL3-targeted antibody drug conjugate	Rova-T	non-significant results
TRINITY100	II	DLL3-targeted antibody drug conjugate	Rova-T	non-significant results
ALTER 1202101	II	tyrosine kinase inhibitor	anlotinib	PFS: 4.1 versus 0.7 (p < 0.0001)
				OS: 7.3 versus 4.9 (p = 0.0210
ClinicalTrials.gov: NCT00154388102	II	tyrosine kinase inhibitor	imatinib	non-significant results
ClinicalTrials.gov: NCT01533181103	II	IGF-R1 inhibitor	linsitinib	non-significant results
ClinicalTrials.gov: NCT00869752104	I	IGF-R1 inhibitor	dalotuzumab	safety: well tolerated
ClinicalTrials.gov: NCT02038647105	II	AURKA inhibitor	alisertib	ORR: 22% versus 18% (p = 0.406)
				PFS: 3.32 versus 2.17 (p = 0.113)
				OS: 6.86 versus 5.58 (p = 0.714)
SALUTE106	II	VEGF inhibitor	bevacizumab	ORR: 58% versus 48%
				PFS: 5.5 versus 4.4
				OS: 9.4 versus 10.9
ClinicalTrials.gov: NCT02454972107	II	RNA polymerase II inhibitor	lurbinectedin	ORR: 35.2%
				PFS: 3.5
				OS: 9.3

PARP, poly(ADP-ribose) polymerase; DLL3, delta-like protein 3; IGF-R1, insulin-like growth factor 1 receptor; AURKA, aurora kinase A; VEGF, vascular endothelial growth factor.

^aIn months.